Skip to main content

Table 1 Trajectory of costs under Medicare Part D for breast cancer adjuvant endocrine agents prior to generic availability

From: Erratum to: Patient costs of breast cancer endocrine therapy agents under Medicare Part D vs with generic formulations

Medication Monthly cost after deductible Monthly cost in gap Monthly cost in catastrophic
Median of state mean costs Median of state mean costs Median of state mean costs
$, (Range of mean costs) $, (Range of mean costs) $, (Range of mean costs)
2007 2010 Change (%) 2007 2010 Change (%) 2007 2010 Change (%)
Arimidex 39.64 (38.37–48.19) 62.83 (60.00–74.75) +58 258.64 (247.44–263.47) 392.84 (375.66–418.58) +52 13.18 (12.68–13.32) 19.65 (19.03–20.93) +49
Aromasin 42.57 (40.72–50.94) 86.50 (81.51–101.08) +103 267.56 (255.21–273.62) 353.98 (351.86–377.07) +32 13.66 (13.07–13.79) 17.70 (17.59–18.85) +30
Femara 41.92 (39.38–51.11) 89.03 (80.95–102.77) +112 277.65 (249.14–282.54) 433.42 (430.46–461.42) +56 14.16 (12.96–14.34) 21.67 (21.55–23.07) +53
Tamoxifen 6.19 (5.95–9.22) 5.98 (5.66–6.75) −3 21.32 (20.36–25.42) 15.52 (15.03–18.90) −27 2.26 (2.20–2.70) 2.60 (2.58–2.75) +15